Ryan Sullivan

Program Director for Melanoma · Mass General Brigham Cancer Institute

Credentials: · · · ·

History

Abbreviated Targeted Therapy to Improve Anti-PD-1 Inhibitor Efficacy in Melanoma
National Cancer Institute · R01
Contact PI · $1.5M · Massachusetts General Hospital
2018–2023
Promoting Bim-Driven Apoptosis Through MAPK Inhibition: A Therapeutic Strategy in Advanced Melanoma
National Cancer Institute · R01
Contact PI · $2.3M · Massachusetts General Hospital
2015–2022
Clinical Development of a Blood Based Assay That Detects the BRAF V600E Mutation in Melanoma and Thyroid Cancer Patients
National Cancer Institute · UH2
Contact PI · $275.7K · Massachusetts General Hospital
2018–2021

CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer
Principal investigator · Not yet recruiting · Phase 1
Cytosite Biopharma Inc.
2025–2029
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
Principal investigator · Completed · Phase 1, Phase 2
OnKure, Inc.
2022–2025
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
Principal investigator · Active not recruiting · Phase 2
Massachusetts General Hospital
2022–2028
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Principal investigator · Active not recruiting · Phase 2
Massachusetts General Hospital
2017–2026